Small cell lung cancer extensive stage
Not recruitingStudy of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer
Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer
- Disease:Small cell lung cancer extensive stage
- Substances:CarboplatinDurvalumab+5
Denmark- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Amgen Inc.












